Compound 22 (TAAR1 antagonist)

From WikiMD's WELLNESSPEDIA


Overview[edit]

Chemical structure of Compound 22

Compound 22 is a chemical compound known for its role as a selective antagonist of the TAAR1 receptor. TAAR1 is a G protein-coupled receptor (GPCR) that is activated by trace amines, which are endogenous compounds structurally similar to monoamine neurotransmitters. Compound 22 is of interest in the field of neuropharmacology due to its potential implications in modulating monoaminergic systems.

Chemical Properties[edit]

Compound 22 is characterized by its specific chemical structure, which allows it to selectively bind to and inhibit the activity of the TAAR1 receptor. The chemical structure of Compound 22 is depicted in the adjacent image. This structural specificity is crucial for its function as an antagonist, as it prevents the receptor from being activated by its natural ligands.

Mechanism of Action[edit]

As a TAAR1 antagonist, Compound 22 functions by binding to the TAAR1 receptor and blocking its activation by endogenous trace amines. This blockade can modulate the activity of monoaminergic systems, which include neurotransmitters such as dopamine, serotonin, and norepinephrine. By inhibiting TAAR1, Compound 22 may influence various physiological and behavioral processes regulated by these neurotransmitters.

Potential Applications[edit]

Research into Compound 22 and other TAAR1 antagonists is ongoing, with potential applications in the treatment of various neuropsychiatric disorders. TAAR1 has been implicated in the regulation of mood, cognition, and reward, suggesting that antagonists like Compound 22 could be useful in conditions such as depression, schizophrenia, and substance use disorders.

Research and Development[edit]

The development of Compound 22 and similar compounds involves extensive pharmacological testing to determine their efficacy, selectivity, and safety profiles. Studies often focus on the compound's ability to modulate monoaminergic activity in animal models, with the aim of translating these findings into potential therapeutic applications in humans.

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.